Angel Garcia Martin
StemTek Therapeutics, Spain
Dr. Angel Garcia Martin obtained his Ph.D. in 1999 at the Universidad Autonoma de Madrid (Spain) and the Centro de Biología Molecular Severo Ochoa under the supervision of Prof. Manuel Fresno Escudero. His work focused on transcriptional regulation of T cell activation by citokines. In 2000 he moved to the National Cancer Institute at Frederick (NIH; USA) for postdoctoral training in oncogene induced apoptosis in the laboratory of Dr. Howard Fearnhead. In this period Dr. Garcia Martin was interested in biochemistry of caspase activation and genomic analisis of apoptosis resistance to genotoxic stress. Dr. Garcia Martin returned to Spain in 2005 as investigator for the genomic regulation of cancer group at Centro de Investigación Príncipe Felipe, Valencia. In 2006 he moved to the Bilbao area to work as a senior researcher at Proteomika SL developing reasearch dedicated to cancer biomarker discovery using proteomic analysis of cancer patient derived body fluids. In March 2007 he joined Inbiomed to start the Regulation of Cell Growth Laboratory. His main research interest is to understand the role of stem cells in cancer through characterization of cancer initiating cells in order to find novel therapeutic and diagnostic/prognostic targets. Later that year he also became Director of Inbiobank, the biorepository of Fundacion Inbiomed dedicated to adult stem cell banking. In July 2013 he co-founded StemTek Therapeutics, a start-up biotech company dedicated to finding new drugs for cancer treatment based on understanding the biology of cancer stem cells. Sine Septemebre that year he is exclusively dedicated to StemTek Therapeutics serving as CSO and member of the Board.
To understand the role of stem cells in cancer through characterization of cancer initiating cells in order to find novel therapeutic and diagnostic/prognostic targets.